Press Release : Roche's faricimab meets primary -2-

and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
 
 
 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2019 employed about 98,000 people worldwide. In 
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 
61.5 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit www.roche.com. 
 
 
 
   *Lucentis(R) (ranibizumab injection) was developed by Genentech, a 
member of the Roche Group. Genentech retains commercial rights in the 
United States and Novartis has exclusive commercial rights for the rest 
of the world. 
 
 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
 
 
   References 
 
   [1] Yau JWY, et al. Global prevalence and major risk factors of diabetic 
retinopathy. Diabetes Care. 2012;35:556-64. 
 
   [2] Zhao Y, Singh, RP. The role of anti-vascular endothelial growth 
factor (anti-VEGF) in the management of proliferative diabetic 
retinopathy. Drugs in Context. 2018;7:212532. 
 
   [3] Sahni J, et al. Simultaneous inhibition of angiopoietin-2 and 
vascular endothelial growth factor-A with faricimab in diabetic macular 
edema. American Academy of Ophthalmology. 2019;126:1155--70. 
 
   [4] FDA. Highlights of prescribing information, Lucentis [Internet; 
cited 2020 November]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf. 
 
 
   [5] Roche data on file. 
 
   [6] Khan M, et al. Targeting Angiopoietin in retinal vascular diseases: 
A literature review and summary of clinical trials involving faricimab. 
Cells. 2020;9(8):1869. 
 
   [7] Clinical Trials.gov. A study to evaluate the long-term safety and 
tolerability of faricimab in participants with diabetic macular edema 
(Rhone-X) [Internet; cited 2020 November]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT04432831. 
 
   [8] Clinical Trials.gov. A study to evaluate the efficacy and safety of 
faricimab in participants with neovascular age-related macular 
degeneration (TENAYA) [Internet; cited 2020 November]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03823287. 
 
   [9] Clinical Trials.gov. A study to evaluate the efficacy and safety of 
faricimab in participants with neovascular age-related macular 
degeneration (LUCERNE) [Internet; cited 2020 November]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03823300. 
 
   [10] Pennington KL, DeAngelis MM. Epidemiology of age-related macular 
degeneration (AMD): associations with cardiovascular disease phenotypes 
and lipid factors. Eye and Vision. 2016;3:34. 
 
   [11] Little K., et al. Myofibroblasts in macular fibrosis secondary to 
neovascular age-related macular degeneration-the potential sources and 
molecular cues for their recruitment and activation. EBioMedicine. 
2018;38:283-91. 
 
   [12] Clinical Trials.gov. A study to evaluate the efficacy and safety of 
faricimab (RO6867461) in participants with diabetic macular edema 
(YOSEMITE) [Internet; cited 2020 November]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03622580. 
 
   [13] Clinical Trials.gov. A study to evaluate the efficacy and safety of 
faricimab (RO6867461) in participants with diabetic macular edema 
(RHINE) [Internet; cited 2020 November]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03622593. 
 
   [14] National Eye Institute. Facts about diabetic eye disease [Internet; 
cited 2020 November]. Available from: 
https://nei.nih.gov/health/diabetic/retinopathy. 
 
   [15] American Optometric Association. Diabetic retinopathy [Internet; 
cited 2020 November]. Available from: 
https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/diabetic-retinopathy. 
 
 
   [16] All About Vision. Macula Lutea [Internet; cited 2020 November]. 
Available from: https://www.allaboutvision.com/resources/macula. 
 
   [17] Liu E, et al. Diabetic macular oedema: clinical risk factors and 
emerging genetic influences. Clinical and Experimental Optometry. 
2017;100:569-76. 
 
   [18] Park SJ, et al. Extent of exacerbation of chronic health conditions 
by visual impairment in terms of health-related quality of life. JAMA 
Ophthalmol. 2015;133:1267--75. 
 
   [19] Holz FG, et al. Multi-country real-life experience of anti-vascular 
endothelial growth factor therapy for wet age-related macular 
degeneration. The British Journal of Ophthalmology. 2015;99:220-6. 
 
   [20] Campochiaro, P, et al. Primary Analysis Results of the Phase 3 
Archway Trial of the Port Delivery System With Ranibizumab for Patients 
With Neovascular AMD. American Society of Retina Specialists Annual 
Meeting; 2020 Jul 24-26. 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: 
https://www.globenewswire.com/Tracker?data=DpB00qwSUT5MKk4jYXmzT-9g9l0-bWtz_SdppvfWXNgMTG-8w8qWWlw3jhSinunZD65sagYXBAdPq00iP42LAqz43mnBwEHkxNZcYHF-tdEeGa5FlhaPTPoqlhjkBkVg 
[e-mail] 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
 
 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
 
 
 
   Attachment 
 
 
   -- 21122020_MR_ Faricimab DME SREP_EN 
      https://ml-eu.globenewswire.com/Resource/Download/3fac8b9c-23d0-4e19-b491-59dcf29856a3

(END) Dow Jones Newswires

December 21, 2020 01:00 ET (06:00 GMT)